NY-ALVAREZ-&-MARSAL
Leading global professional services firm Alvarez & Marsal (A&M) has announced the promotion of 69 professionals, across Europe and Middle East, India, Latin America, North America, North Asia and Southeast Asia & Australia to the position of Managing Director.
Tony Alvarez II and Bryan Marsal, A&M’s Co-Founders, stated, “Congratulations to all our newly promoted Managing Directors. Their contributions to our core values of integrity, quality, objectivity, fun, personal reward and inclusive diversity are what make A&M unique. Their commitment to help clients maximize value and drive change amidst ongoing macro-economic challenges builds upon our legacy of operational excellence while advancing our results-oriented mission. They, alongside all A&M professionals, are our greatest strength.”
2024 MANAGING DIRECTOR PROMOTIONS
Europe and Middle East
- Cristiano Battelli, Private Equity Performance Improvement -- Milan
- Paul Culham, Global Transaction Advisory Group -- London
- Louis Darrieus, Global Transaction Advisory Group -- Paris
- Steve Green, Debt Advisory -- London
- Josefine Haensel, Corporate Transformation Services -- Hamburg
- Samih Hajar, Global Transaction Advisory Group -- Paris
- Cheng He, Global Transaction Advisory Group -- London
- Michal Kapela, Global Transaction Advisory Group -- Zurich
- Zeeshan Mansoor, Financial Services Industry -- Amsterdam
- Michael Nizet, Financial & Operational Restructuring -- Amsterdam
- Robert Park, Corporate Transformation Services -- London
- Tom Paterson, Debt Advisory -- London
- Adam Paxton, Insolvency -- London
- Felix Schweigger, Private Equity Performance Improvement -- Munich
- Steve Smith, Tax -- London
- Sebastien Trochet, Digital & Technology Services -- Paris
- Yann Varin, Private Equity Performance Improvement -- Paris
- Nick Walton, Tax -- Manchester
India
- Ashish Doshi, Global Transaction Advisory Group -- Mumbai
- Ram Panda, Business Transformation Services -- Mumbai
Latin America
- Guilherme Almeida, Corporate Transformation -- São Paulo
- Luiz Gronau, Infrastructure & Capital Projects (A&M INFRA) -- São Paulo
- Eduardo Magalhaes, Global Disputes and Investigations -- São Paulo
North America
- Richard Behrens, North American Commercial Restructuring -- Los Angeles
- Brett Bergamo, Energy -- Houston
- Amy Best, Global Disputes and Investigations -- Denver
- Matthew Box, Healthcare -- Washington, D.C.
- Aaron Busse, Corporate Performance Improvement -- Atlanta
- Meghan Cardell, Global Disputes and Investigations -- Washington, D.C.
- Evan Colwell, Global Transaction Advisory Group -- Nashville
- Steve Coverick, North American Commercial Restructuring -- Dallas
- Jorge de Los Reyes, Infrastructure & Capital Projects (A&M INFRA) -- Washington, D.C.
- Beata De Zagon, Global Transaction Advisory Group -- Dallas
- Alex Duff, Private Equity Performance Improvement -- New York
- Ryan Duffy, Global Transaction Advisory Group -- Chicago
- Kyle Foust, Tax -- Chicago
- Max Fulton, Private Equity Performance Improvement -- Denver
- Jen Fults, Tax -- New York
- Jeffrey Gerarde, Tax -- Washington, D.C.
- John Hanson, North American Commercial Restructuring -- Dallas
- Sam Jones, Global Transaction Advisory Group -- Chicago
- Andrew Khoo, North American Commercial Restructuring -- New York
- David Knight, Private Equity Performance Improvement -- Houston
- Daniel LaMantia, Private Equity Performance Improvement -- Dallas
- Erin Leveton, Public Sector Services -- Washington, D.C.
- Allen Mahr, North American Commercial Restructuring -- New York
- Matthew Merhan, Corporate Performance Improvement -- Houston
- Derek Myers, Tax -- Atlanta
- Rich Niemerg, North American Commercial Restructuring -- Chicago
- Alan Pender, Energy -- Dallas
- Rob Reid, Infrastructure & Capital Projects (A&M INFRA) -- Atlanta
- Jeffrey Richman, Corporate Finance -- New York
- Brian Rudelson, Tax -- Houston
- Joan Russo, Healthcare -- Miami
- Paul Saftig, Global Transaction Advisory Group -- Chicago
- John Sawyer, Valuation -- Seattle
- Daniel Schmeltz, Corporate Performance Improvement -- Houston
- Jigar Shah, Corporate Performance Improvement -- Los Angeles
- Michael Shanahan, Global Disputes and Investigations -- Philadelphia
- Jeff Swerdlow, Tax -- Denver
- Andrew Thung, Healthcare -- New York
- Jeremy Tilsner, Global Disputes and Investigations -- New York
- Andrey Ulyanenko, Tax -- Miami
- Aaron Umberger, Public Sector Services -- Washington, D.C.
- Mariya Verbitski, Global Transaction Advisory Group -- San Francisco
North Asia
- Dee Chung, Restructuring & Turnaround -- Seoul
- Carmen Yeung, Restructuring & Turnaround -- Hong Kong SAR
Southeast Asia & Australia
- John Sanger, Performance Improvement -- Perth
- Kaustav Sen, Performance Improvement -- Singapore
About Alvarez & Marsal
Companies, investors and government entities around the world turn to Alvarez & Marsal (A&M) for leadership, action and results. Privately held since its founding in 1983, A&M is a leading global professional services firm that provides advisory, business performance improvement and turnaround management services. When conventional approaches are not enough to create transformation and drive change, clients seek our deep expertise and ability to deliver practical solutions to their unique problems.
With over 8,500 people across six continents, we deliver tangible results for corporates, boards, private equity firms, law firms and government agencies facing complex challenges. Our senior leaders, and their teams, leverage A&M’s restructuring heritage to help companies act decisively, catapult growth and accelerate results. We are experienced operators, world-class consultants, former regulators and industry authorities with a shared commitment to telling clients what’s really needed for turning change into a strategic business asset, managing risk and unlocking value at every stage of growth.
To learn more, visit: AlvarezandMarsal.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240109034313/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom